LipiControl

LipiControl®

Heart health remains a primary concern for many people and effective, natural products exist to promote heart health.

Designed for those who want help maintaining healthful levels of fats and sterols in the blood, LipiControl® is a powerful and effective combination of herbs and vitamins that have been shown to support and manage healthy lipid levels, vascular (blood vessel) function and circulation.*

LipiControl combines the non-flush form of niacin (vitamin B3) with balanced amounts of gamma oryzanol, beta-sitosterol, red yeast and guggulipid, standardized to 10 percent guggulsterones.

It would be prudent for individuals who take LipiControl® to consider supplementing with coenzyme Q10, another supplement well-documented for heart health, in addition to practicing good dietary choices.

Product Code: 1960
Name: LipiControl®
Description: 180 capsules

Supplement Facts
Serving Size:1 capsule

Amount Per Serving % Daily Value

Niacin 167 mg 835%
(vitamin B as inositol hexanicotinate)
Inositol 41.75 mg *
(as inositol hexanicotinate)
Beta Sitosterol 50 mg *
Gamma Oryzanol 50 mg *
Red Yeast (Monascus purpureus) 350 mg *
extract (from rice)
Gugulipid (Commiphora mukul) 125 mg *
(10% guggulsterones)

*Daily Value not established

Other Ingredients:
Hydroxypropyl methylcellulose (Vcap).

Contains no added starch, salt, wheat, gluten,
corn, coloring, or dairy products.

Keep container tightly closed in a cool,
dry and dark place. Keep out of reach of children.

Recommended Dosage: two capsules three times per day.

Cautions:
Red Yeast may cause muscle cramps, weakness and fatigue. These symptoms are likely due to the extract's inhibition of CoQ10 activity, and may be relieved by increasing the dosage of CoQ10. Red Yeast extract may also cause significant elevations in liver enzymes in approximately 1% of those who take it. Red Yeast extract should not be taken by those with a history of liver disease unless under the supervision of a health care professional. We suggest that the liver enzymes be monitored periodically.

Elevated levels of serum cholesterol (hypercholesterolemia) are recognized as a risk factor for developing Coronary Heart Disease (CHD), the leading cause of death in the United States.1 A number of food-source supplements have recently been shown effective at lowering total cholesterol levels, reducing LDL and triglyceride levels, and increasing HDL levels. LipiControl combines a number of these agents (including gamma oryzanol, niacin and red yeast rice extract) that have been shown effective for reducing abnormally high levels of blood lipids and lowering risk of coronary heart disease.

Red Yeast Rice Extract

Chinese red yeast rice extract contains cholesterol-lowering compounds known as statins, among them lovastatin—the same active ingredient in Mevacor™. Statins work by inhibiting the key enzyme (HMG-CoA reductase) responsible for producing cholesterol in the body. HMG-CoA reductase catalyzes an essential step in the biosynthesis of cholesterol.

Research has shown that red yeast rice extract significantly reduces total cholesterol, LDL cholesterol and triglycerides and increases HDL cholesterol. In one placebo-controlled clinical trial, eighty-eight patients randomly received either 2400 mg a day of red yeast rice extract or placebo. Blood lipid analysis was conducted after eight and twelve weeks. With treatment, total cholesterol was 16.8% lower after 8 weeks and 16.0% lower after 12 weeks. LDL-cholesterol dropped 21.4% after 8 weeks and 22.0% after 12 weeks. Triglycerides dropped 11.3% after 8 weeks. The HDL-cholesterol remained unchanged throughout the study in both groups.3

The results of another trial using red yeast rice extract found that patients receiving red yeast rice extract experienced a total cholesterol drop of 23%, LDL-cholesterol dropped 28.5%, triglycerides dropped 36.5% and HDL-cholesterol increased 19.6%.4

Inositol Hexanicotinate

Inositol hexanicotinate (IHN), also known as inositol niacinate, is a flush-free form of niacin. The side effects of niacin which may occur at the dosages required for therapeutic efficacy, ranging from flushing and pruritus to hepatoxicity (timed released niacin) and impaired glucose tolerance. By contrast, IHN does not produce these side effects.

Studies have reported significant lipid-lowering effects of IHN at doses of 400 mg, 3-4 times daily. Welsh and Eade found IHN more effective than niacin in its hypocholesterolemic, antihypertensive and lipotropic effects.5 Like niacin, IHN lowers LDL cholesterol, Lp(a) lipoprotein, triglyceride, and fibrinogen levels while simultaneously raising HDL cholesterol levels

IHN has demonstrated its effectiveness in treating other conditions besides hyperlipidemias, such as peripheral vascular disorders of Raynaud’s disease and intermittent claudication.

The mechanisms of action of inositol hexanicotinate are similar to those for niacin. Niacin appears to affect blood lipids by a number of different mechanisms. It lowers LDL and triglyceride levels by decreasing VLDL synthesis, which results in a decrease in the LDL cholesterol fraction. The decrease in VLDL and LDL then leads to a decrease in serum triglycerides, phospholipids and cholesterol, which generally combine with these lipoproteins. Niacin also inhibits cholesterol synthesis from acetate in the liver and increases its degradation. Niacin also reduces coronary artery disease by altering the function of lipoprotein A-I and reducing synthesis of lipoprotein A-II. This appears to result in an elevation of HDL levels.6-8

Gugulipid Extract

Guggul contains ketonic steroid compounds—guggulsterones—that account for its lipid-lowering action. Guggulsterones significantly lower serum triglycerides and cholesterol as well as LDL and VLDL cholesterol. At the same time, they raise levels of HDL cholesterol (the “good” cholesterol).9

In human clinical trials of gugulipid, cholesterol dropped 14-27% while triglyceride levels dropped from 22-30% in a 4 to 12 week period. Studies have shown that the effect of gugulipid on serum cholesterol and triglycerides is superior to the lipid-lowering drugs, clofibrate and cholestyramine. Both of these drugs are associated with some degree of toxicity. By contrast, gugulipid is free of side effects and nontoxic.10-12

Gugulipid also reduces the stickiness of platelets, prevents the heart from being damaged by free radicals and improves the metabolism of the heart. It has prevented the formation of atherosclerosis and helps regress pre-existing atherosclerotic plaques in animals.

Beta Sitosterol

Beta sitosterol is a plant sterol that has been found to reduce blood levels of cholesterol by blocking its absorption. In one study beta-sitosterol resulted in an increase of the fractional and the molar esterification rate of the LCAT. These alterations were associated with a decrease of the levels of total, esterified, and unesterified cholesterol.13

Conclusion

The agents in LipiControl safely reduce serum LDL cholesterol, triglycerides, Lp(a) lipoprotein and fibrinogen and simultaneous raise HDL cholesterol levels. LipiControl also decreases the risk of coronary heart disease by increasing fibrinolysis, scavenging free radical molecules, and antagonizing the formation of atherosclerotic plaque.

References:

1. National Health and Nutrition Examination Study III (NHANES III, 1988–94) (CDC) NCHS.

2. Perreault S, et al. Treating hyperlipidemia for the primary prevention of coronary disease. Are higher doses of lovastatin cost-effective? Arch Intern Med 1998; 158:375-381.

3. Heber D, Yip I, Ashley JM, Elashoff DA, Elashoff RM, Go VL. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr 1999 Feb 69:2 231-6

4. Wang J, Zongliang L, Chi J, et al. Multicenter clinical trial of the serum lipid-lowering effects of a Monascus Purpureus (Red Yeast) rice preparation from traditional Chinese medicine. Current Therapeutic Research 1997; 58(12):964-78

5. Welsh AL and Ede M, Inositol hexanicotinate for improved nicotinic acid therapy. Int Record Med 174, 9-15, 1961.

6. The Coronary Drug Project Group, Clofibrate and niacin in coronary heart disease. JAMA 231, 360-381, 1975.

7. Canner PL, et al., Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacin. J Am Coll Cardiol 8, 1245-1255, 1986.

8. Illingworth DR, et al., Comparative effects of lovastatin and niacin in primary hypercholesterolemia. Arch Intern Med 154, 1586-1595,1994.

9. Satyavati GV: Gugulipid: a promising hypolipidaemic agent from gum guggul (Commiphora wightii) Econ Med. Plant Res, 47-82, 1991

10. Satyavati GV, et al: Experimental studies of the hypocholesterolemic effect of Commiphora-mukul. Ind J Med Res 57:1950-62, 1969.

11. Nityand S and Kapoor NK: Hypocholesterolemic effect of Commiphora mukul resin. Ind J Exp Biol 9:376-7, 1971

12. Verna SK and Bordia A Effect of Commiphora mukul (gum guggul) in patients of hyperlipidemia with special reference to HDL cholesterol. Ind J Med Res 87:356-60, 1988

13. Lees AM, Mok HYI, Lee RS, et al. Plant sterols as cholesterol-lowering agents: Clinical trials in patients with hypercholesterolemia and studies of sterol balance. Atheroscler 1977;28:325–38.

Reprinted with permission from Vitamin Research Products (888) 891-1800. Statements made in this article have not been evaluated by the FDA, and are not intended to diagnose, treat or prevent any disease.

There are currently no reviews of this product.
Submit a Review